StockData
Transcode Therapeutics, Inc. logo

Transcode Therapeutics, Inc. (RNAZ) stock

RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.30−0.04 (-3.35%)

Close on Nov 19, 2026Market cap $1.32MP/E –Yield –

Transcode Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Transcode Therapeutics's free cash flow for the twelve months ending Dec 31, 2024 was -$13.36M. For fiscal 2025 it was -$19.52M. The highest annual figure on record is -$5.52M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$19.52M–
FY2024Dec 31, 2024-$13.36M–
FY2023Dec 31, 2023-$18.11M–
FY2022Dec 31, 2022-$15.86M–
FY2021Dec 31, 2021-$5.52M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024-$3.15M–
Q3 FY2024Sep 30, 2024-$3.93M–
Q2 FY2024Jun 30, 2024-$2.34M–
Q1 FY2024Mar 31, 2024-$3.94M–
Q4 FY2023Dec 31, 2023-$5.66M–
Q3 FY2023Sep 30, 2023-$3.51M–
Q2 FY2023Jun 30, 2023-$4.41M–
Q1 FY2023Mar 31, 2023-$4.53M–
Q4 FY2022Dec 31, 2022-$4.05M–
Q3 FY2022Sep 30, 2022-$4.42M–
Q2 FY2022Jun 30, 2022-$3.41M–
Q1 FY2022Mar 31, 2022-$3.98M–
Q4 FY2021Dec 31, 2021-$1.69M–
Q3 FY2021Sep 30, 2021-$3.14M–
Q2 FY2021Jun 30, 2021-$98.24K–
Q1 FY2021Mar 31, 2021-$597.45K–

More Transcode Therapeutics figures

See a number that looks wrong?